Qiagen N.V. (QGEN) Shares Bought by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. increased its holdings in shares of Qiagen N.V. (NASDAQ:QGEN) by 3.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 188,102 shares of the company’s stock after acquiring an additional 6,557 shares during the period. Schwab Charles Investment Management Inc. owned about 0.08% of Qiagen N.V. worth $6,308,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Sei Investments Co. grew its position in Qiagen N.V. by 47.1% during the 2nd quarter. Sei Investments Co. now owns 176,419 shares of the company’s stock worth $5,915,000 after acquiring an additional 56,489 shares during the last quarter. Johnston Asset Management LLC grew its position in Qiagen N.V. by 1.1% during the 2nd quarter. Johnston Asset Management LLC now owns 3,612,479 shares of the company’s stock worth $121,126,000 after acquiring an additional 39,145 shares during the last quarter. Public Employees Retirement Association of Colorado grew its position in Qiagen N.V. by 3.5% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 7,214 shares of the company’s stock worth $242,000 after acquiring an additional 246 shares during the last quarter. Parametrica Management Ltd grew its position in Qiagen N.V. by 44.0% during the 2nd quarter. Parametrica Management Ltd now owns 14,555 shares of the company’s stock worth $488,000 after acquiring an additional 4,448 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its position in Qiagen N.V. by 19.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 286,553 shares of the company’s stock worth $9,596,000 after acquiring an additional 47,657 shares during the last quarter. Institutional investors and hedge funds own 63.01% of the company’s stock.

QGEN has been the topic of several research reports. Zacks Investment Research downgraded Qiagen N.V. from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. BidaskClub raised Qiagen N.V. from a “hold” rating to a “buy” rating in a report on Wednesday, July 19th. Wells Fargo & Company reaffirmed a “market perform” rating and set a $31.00 price objective (up previously from $28.00) on shares of Qiagen N.V. in a report on Thursday, July 13th. Jefferies Group LLC reaffirmed a “hold” rating and set a $28.00 price objective (up previously from $25.00) on shares of Qiagen N.V. in a report on Monday, July 31st. Finally, Commerzbank Ag reaffirmed a “buy” rating on shares of Qiagen N.V. in a report on Thursday, August 17th. Eight research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $33.28.

ILLEGAL ACTIVITY WARNING: “Qiagen N.V. (QGEN) Shares Bought by Schwab Charles Investment Management Inc.” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://ledgergazette.com/2017/10/11/qiagen-n-v-qgen-shares-bought-by-schwab-charles-investment-management-inc.html.

Qiagen N.V. (NASDAQ:QGEN) opened at 34.64 on Wednesday. Qiagen N.V. has a 1-year low of $24.89 and a 1-year high of $35.47. The stock has a 50 day moving average price of $32.22 and a 200-day moving average price of $32.11. The firm has a market cap of $7.91 billion, a P/E ratio of 105.93 and a beta of 1.14.

Qiagen N.V. (NASDAQ:QGEN) last posted its earnings results on Thursday, July 27th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.02. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. The firm had revenue of $349.00 million for the quarter, compared to analysts’ expectations of $353.09 m

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Sei Investments Co. grew its position in Qiagen N.V. by 47.1% during the 2nd quarter. Sei Investments Co. now owns 176,419 shares of the company’s stock worth $5,915,000 after acquiring an additional 56,489 shares during the last quarter. Johnston Asset Management LLC grew its position in Qiagen N.V. by 1.1% during the 2nd quarter. Johnston Asset Management LLC now owns 3,612,479 shares of the company’s stock worth $121,126,000 after acquiring an additional 39,145 shares during the last quarter. Public Employees Retirement Association of Colorado grew its position in Qiagen N.V. by 3.5% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 7,214 shares of the company’s stock worth $242,000 after acquiring an additional 246 shares during the last quarter. Parametrica Management Ltd grew its position in Qiagen N.V. by 44.0% during the 2nd quarter. Parametrica Management Ltd now owns 14,555 shares of the company’s stock worth $488,000 after acquiring an additional 4,448 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its position in Qiagen N.V. by 19.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 286,553 shares of the company’s stock worth $9,596,000 after acquiring an additional 47,657 shares during the last quarter. Institutional investors and hedge funds own 63.01% of the company’s stock.

QGEN has been the topic of several research reports. Zacks Investment Research downgraded Qiagen N.V. from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. BidaskClub raised Qiagen N.V. from a “hold” rating to a “buy” rating in a report on Wednesday, July 19th. Wells Fargo & Company reaffirmed a “market perform” rating and set a $31.00 price objective (up previously from $28.00) on shares of Qiagen N.V. in a report on Thursday, July 13th. Jefferies Group LLC reaffirmed a “hold” rating and set a $28.00 price objective (up previously from $25.00) on shares of Qiagen N.V. in a report on Monday, July 31st. Finally, Commerzbank Ag reaffirmed a “buy” rating on shares of Qiagen N.V. in a report on Thursday, August 17th. Eight research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $33.28.

ILLEGAL ACTIVITY WARNING: “Qiagen N.V. (QGEN) Shares Bought by Schwab Charles Investment Management Inc.” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://ledgergazette.com/2017/10/11/qiagen-n-v-qgen-shares-bought-by-schwab-charles-investment-management-inc.html.

Qiagen N.V. (NASDAQ:QGEN) opened at 34.64 on Wednesday. Qiagen N.V. has a 1-year low of $24.89 and a 1-year high of $35.47. The stock has a 50 day moving average price of $32.22 and a 200-day moving average price of $32.11. The firm has a market cap of $7.91 billion, a P/E ratio of 105.93 and a beta of 1.14.

Qiagen N.V. (NASDAQ:QGEN) last posted its earnings results on Thursday, July 27th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.02. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. The firm had revenue of $349.00 million for the quarter, compared to analysts’ expectations of $353.09 million. During the same quarter in the previous year, the firm posted $0.24 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. Equities research analysts forecast that Qiagen N.V. will post $1.21 EPS for the current year.

Qiagen N.V. Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NASDAQ:QGEN).

Institutional Ownership by Quarter for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply